30th Oct 2025 10:00
(Alliance News) - Haleon PLC on Thursday reported a "good performance" in the third quarter,
with broad-based geographic growth and a stand-out showing in Oral Health.
The Weybridge, Surrey-based consumer goods firm owns products such as oral health brand Sensodyne and Panadol pain killers.
Revenue rose 0.7% to GBP2.80 billion in the third quarter of 2025 from GBP2.78 billion the year prior, or by 3.4% on an organic basis, reflecting price up 1.8% and volume/mix up 1.6%.
By geography, sales rose 5.3% in Europe, Middle East & Africa and Latin America, by 5.1% in Asia Pacific and by a more modest 0.4% in North America on an organic basis.
Emerging markets revenue increased 7.1%, with India up double digits and China up mid-single digit.
By product, Haleon reported organic sales growth of 6.9% in Oral Health, 4.9% in Vitamins, Minerals, and Supplements, 3.7% in Pain Relief and 2.1% in Digestive Health.
Organic sales fell 1.8% in Respiratory Health and by 1.1% in Therapeutic Skin Health and Other.
Haleon highlighted the "continued outperformance" in Oral Health and said VMS was underpinned by strong growth in Centrum multivitamins in EMEA & LatAm.
Chief Executive Brian McNamara said Haleon delivered a "good performance" in the third quarter.
"All regions delivered positive organic revenue growth, driven by strong in-market execution and the continued roll-out of our innovation pipeline," he noted.
"Oral Health was the standout performer, with innovation driving strong market share gains for Sensodyne and parodontax. VMS also delivered a good performance, supported by new launches for
Centrum, Emergen-C, and Caltrate," he added.
"We are on track to deliver our FY guidance and remain confident in our medium-term outlook," he continued.
Haleon reiterated 2025 guidance and expects organic revenue growth to be around 3.5% assuming a normal cold and flu season.
Positive operating leverage is expected to deliver high single digit organic operating profit growth.
In 2024, Haleon reported sales of GBP11.23 billion and operating profit of GBP2.21 billion.
Shares in Haleon were up 2.4% at 353.30 pence each in London on Thursday morning.
By Jeremy Cutler, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Haleon